petosemtamab (MCLA-158) - Merus
trastuzumab pamirtecan (BNT323) - BioNTech
sonesitatug vedotin (AZD0901) - AstraZeneca
delpacibart etedesiran (AOC 1001) - Avidity Biosci
izalontamab brengitecan (BL-B01D1) - Biokin Pharma, BMS
delpacibart zotadirsen (AOC-1044) - Eli Lilly
Herceptin (trastuzumab) - Roche
ifinatamab deruxtecan (DS-7300) - Daiichi Sankyo, Merck (MSD)
izalontamab (SI-B001) - Biokin Pharma
http://www.ncbi.nlm.nih.gov/pubmed/41560619
 
Alicia Chenoweth; Hélène Kaplon; Janice M Reichert; Kieran Pinto; Silvia Crescioli; Vaishali Kapoor; Yu-Shin Hsu
 
Jan 21, 2026
 
Prev Next